Targretin oral (bexarotene oral) / ReXceptor 
Welcome,         Profile    Billing    Logout  
 95 Diseases   5 Trials   5 Trials   746 News 


«12345678910»
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Review, Journal:  The novel function of bexarotene for neurological diseases. (Pubmed Central) -  Sep 7, 2023   
    For other neurological diseases, its mechanisms of action include inhibiting inflammatory responses, up-regulating microglial phagocytosis, and reducing misfolded protein aggregation, all of which aid in alleviating neurological damage. Here, we briefly discuss the characteristics, applications, and adverse effects of bexarotene, summarize its pharmacological mechanisms and therapeutic results in various neurological diseases, and elaborate on the problems encountered in preclinical research, with the aim of providing help for the further application of bexarotene in central nervous system diseases.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    FDA event, Journal:  Structure based virtual screening and molecular simulation study of FDA-approved drugs to inhibit human HDAC6 and VISTA as dual cancer immunotherapy. (Pubmed Central) -  Sep 7, 2023   
    Here, we briefly discuss the characteristics, applications, and adverse effects of bexarotene, summarize its pharmacological mechanisms and therapeutic results in various neurological diseases, and elaborate on the problems encountered in preclinical research, with the aim of providing help for the further application of bexarotene in central nervous system diseases. Our study revealed that Oxymorphone and Bexarotene are the top-ranked inhibitors of VISTA and HDAC6, respectively...The binding free energy score of Oxymorphone/VISTA and Ref/VISTA were calculated as -?36.8323?
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Bexarotene in Patients With Peripheral T?Cell Lymphomas: Results of a Retrospective Study () -  Aug 31, 2023 - Abstract #SOHO2023SOHO_915;    
    Our study revealed that Oxymorphone and Bexarotene are the top-ranked inhibitors of VISTA and HDAC6, respectively...The binding free energy score of Oxymorphone/VISTA and Ref/VISTA were calculated as -?36.8323? Bexarotene monotherapy is well-tolerated and is well tolerated in PTCL that documents further investigation in prospective clinical trials.
  • ||||||||||  Poteligeo (mogamulizumab) / Kyowa Kirin
    Mogamulizumab?Associated Rash in Patients With Mycosis Fungoides and S () -  Aug 31, 2023 - Abstract #SOHO2023SOHO_909;    
    The frequency and persistence of MAR in clinical practice appears greater than previously described. Given the high efficacy and response durability to mogam, understanding precipitating factors and effective treatments for MAR is critical to better application of mogam for patients with CTCL.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda
    Brentuximab in the treatment of S (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_3201;    
    Given the high efficacy and response durability to mogam, understanding precipitating factors and effective treatments for MAR is critical to better application of mogam for patients with CTCL. At this point, treatment with mogamulizumab was considered, but the patient
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor, Adcetris (brentuximab vedotin) / Seagen, Takeda
    Esophagic metastases in a patient with mycosis fungoides (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_3172;    
    We present this case due to the infrequent extracutaneous involvement: tumor stages increase the probability of systemic dissemination, although esophageal involvement is exceptional. Follow-up adapted to the tumor stage is required for early detection of metastases.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Journal:  Automated production of C-labeled carboxylic acids and esters via "in-loop" C-carbonylation using GE FX synthesis modules. (Pubmed Central) -  Aug 23, 2023   
    The reaction proceeds at room temperature under mild conditions and enables C-carbonylation of both electron deficient and electron rich (hetero)aromatic halides to provide C-carboxylic acids and esters in good to excellent radiochemical yields, high radiochemical purity, and excellent molar activity. The process has been fully automated using commercial radiochemistry synthesis modules, and application to clinical production is demonstrated via validated cGMP radiosyntheses of [ C]bexarotene and [ C]acetoacetic acid.
  • ||||||||||  Poteligeo (mogamulizumab) / Kyowa Kirin, Targretin oral (bexarotene oral) / ReXceptor, Adcetris (brentuximab vedotin) / Seagen, Takeda
    What We Have Learnt About The Treatment of Advanced Stage MF from the PROCLIPI Study () -  Jul 24, 2023 - Abstract #EORTCCLTF2023EORTC_CLTF_159;    
    First line treatment choices are selected according to clinical stage, ECP is the most frequent first line therapy and has superior TTNsT at 36.6 months. In second line therapy there is more heterogeneity in treatment choices with bexarotene in 13.5% being the most frequent.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor, idazoxan (RX 781094) / Houston Pharma
    Review, Journal:  Novel pharmacotherapy targeting the positive symptoms of schizophrenia. (Pubmed Central) -  Jul 4, 2023   
    Mirtazapine could be useful for treating negative symptoms without increasing the risk of a worsening of delusions/hallucinations. Nevertheless, the lack of replication of studies prevents to draw definitive conclusions and future studies are needed to confirm the findings presented in this overview.
  • ||||||||||  acitretin / Generic mfg.
    Use of acitretin for mycosis fungoides: results of a retrospective study () -  Jul 3, 2023 - Abstract #WCD2023WCD_5355;    
    IIB) that systemic treatments are used, including retinoids. In clinical practice, acitretin is most frequently used in cases of extensive lesions, relapsing after topical treatments and phototherapy and in case of contraindication to other immunomodulators.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Mucosal involvement in a patient with cutaneous CD30-positive T-cell lymphoproliferative disorders () -  Jul 3, 2023 - Abstract #WCD2023WCD_5334;    
    KEY MESSAGE: In this case of cutaneous CD30-positive T-cell lymphoproliferative disorders, a monoclonal population of T-lymphocytos in both mucosal and skin lesions were revealed by anaylysis of TCR?gene rearrangement. In such a case, the necessity for therapy by aggressive therapies, such as systemic chemotherapy, should be carefully judged
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Journal:  Bexarotene use in refractory Darier's disease. (Pubmed Central) -  Jun 29, 2023   
    Further studies for optimizing the initial bexarotene dose in such patients are required. No abstract available
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Statin use inhibits cutaneous T-cell lymphoma growth via inducing KLF2 upregulation (Level 3 - Room 320) -  Jun 2, 2023 - Abstract #WCD2023WCD_3570;    
    These results provide new insights into the pathogenic mechanisms of KLF2 underlying CTCL progression. Stains, clinically lipid-lowering drugs, may play a novel role in CTCL therapy via inducing KLF2 overexpression
  • ||||||||||  Poteligeo (mogamulizumab) / Kyowa Kirin
    MOGAMULIZUMAB IN MYCOSIS FUNGOIDES AND S () -  May 12, 2023 - Abstract #EHA2023EHA_2703;    
    The treatment was well tolerated and no safety concern was noticed. Cutaneous T-cell lymphoma, Mycosis fungoides
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Bexarotene: A Deceptive Cause of Iatrogenic Hypothyroidism (ENDOExpo) -  May 11, 2023 - Abstract #ENDO2023ENDO_2122;    
    Oral Bexarotene can cause central hypothyroidism therefore, thyroid function tests should be measured at baseline and treatment. Thyroid hormone replacement should be considered if central hypothyroidism is suspected.
  • ||||||||||  Poteligeo (mogamulizumab) / Kyowa Kirin, Targretin oral (bexarotene oral) / ReXceptor
    Biomarker, Review, Journal, IO biomarker:  New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications. (Pubmed Central) -  May 1, 2023   
    Recent molecular advancements have contributed to our understanding of the pathogenesis of CTCL and shed light into the potential mechanisms of existing therapies. Further understanding of the CTCL TME may fuel the discovery of novel therapies for CTCL.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Relevant factors for dosing period of bexarotene treatment in Japanese patients with mycosis fungoides: A post-hoc analysis from accumulated post-marketing surveillance data () -  Mar 4, 2023 - Abstract #ISID2023ISID_972;    
    The limitations of this study included the lack of randomization, a selection bias resulting from the inability to capture all Japanese patients with MF, and differences in combination photo(chemo)therapy contents (e.g., dosing, treatment period, and treatment frequency). These exploratory analyses indicate that bexarotene treatment with a combination of photo(chemo)therapy may offer a promising efficacy on dosing period for Japanese patients with MF, regardless of initial dose of bexarotene, prior systemic therapies and clinical stage (early-stage vs. advanced-stage).
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor, endurobol (GW501516) / Ligand, GSK
    Journal:  Regulation of adipogenesis through retinoid X receptor and/or peroxisome proliferator-activated receptor by designed lignans based on natural products in 3T3-L1 cells. (Pubmed Central) -  Feb 27, 2023   
    In a manner similar to 6OHE and 6OHA, bexarotene, an RXR agonist, suppressed adipocyte differentiation, and its anti-adipogenic effect was reversed by an RXR antagonist...We demonstrated the adipogenic effect of 4'OHE and anti-adipogenic effects of 6OHE and 6OHA in 3T3-L1 cells. Previously, RXR agonists have been reported to positively regulate the differentiation of mesenchymal stem cells into adipocytes, but our current data showed that they inhibited the differentiation of preadipocytes, at least 3T3-L1 cells, into adipocytes.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    SELECTIVE ACTIVATION OF LXRS AND RXRS REGULATES SYNTHESIS, RELEASE AND LIPIDATION OF HEPATIC APOE IN HEPATOCARCINOMA CELL LINES (EXHIBITION) -  Dec 23, 2022 - Abstract #ADPD2023ADPD_1384;    
    Effects of LXR and RXR agonists (T0901917/GW3965 and Bexarotene/9 -cis-retinoic acid) on ApoE and ABCA1 levels in cell supernatants and pellets were evaluated after 24/48hrs... Hepatic ApoE and ABCA1 synthesis/release from human APOE ?3 homozygous hepatocarcinoma cells can be modulated by LXR/RXR agonists with potential implications to ApoE3 dimer and lipoparticle formation
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    HOW AMYLOID BETA FIBRILS GROW AND HOW POTENTIAL DRUGS SUPPRESS THEIR GROWTH (On-Demand Oral Gallery H) -  Dec 23, 2022 - Abstract #ADPD2023ADPD_545;    
    Hepatic ApoE and ABCA1 synthesis/release from human APOE ?3 homozygous hepatocarcinoma cells can be modulated by LXR/RXR agonists with potential implications to ApoE3 dimer and lipoparticle formation Drug -driven polymorph transformation presents a mode of act ion to irreversibly suppress toxic aggregates not only in Alzheimer's, but also potentially in myriad diverse pathologies that originate with protein condensation.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor, Kalydeco (ivacaftor) / Vertex, Zelboraf (vemurafenib) / Roche
    Journal:  Novel Inhibitors of Breast Cancer Resistance Protein (ABCG2) Among Marketed Drugs. (Pubmed Central) -  Dec 19, 2022   
    Moreover, a mechanistic static model suggested that vemurafenib, bexarotene, dabigatran etexilate, rifapentine, aprepitant, and ivacaftor could almost fully inhibit intestinal BCRP, increasing the exposure of concomitantly administered rosuvastatin over 90%. Therefore, clinical studies are warranted to investigate whether these drugs cause BCRP-mediated DDIs in humans.
  • ||||||||||  Efficacy of Combinatorial Treatment Approaches in CTCL () -  Nov 29, 2022 - Abstract #ASH2022ASH_7346;    
    Over the past 20 years only six novel biological/targeted agents (bexarotene, denileukin diftitox, vorinostat, romidepsin, brentuximab vedotin, mogamulizumab) have been FDA approved for systemic therapy of relapsed/refractory MF/SS however, none render curative approach...Out of the 7 pts that did respond, the most prevailing treatment was the combination of Venetoclax and Duvelisib with 6 out of 7 pts samples having a response to this combination...Our observations on MF/SS pts samples thus far demonstrates various sensitivities to treatments for individual pts. This may account for genetic and epigenetic changes which highlight the unmet need for personalization of treatment and sensitivity screening for each patient, with the decisive goal to offer a personalized and efficacious treatment modalities.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Journal:  Chromatin accessibility dynamics dictate renal tubular epithelial cell response to injury. (Pubmed Central) -  Nov 29, 2022   
    Activation of RXRα by bexarotene, an FDA-approved RXRα agonist, restores the chromatin state and gene expression program to protect TECs against severe kidney injury. Together, our findings elucidate a chromatin-mediated mechanism underlying differential responses of TECs to varying injuries and identify RXRα as a therapeutic target of acute kidney injury.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Journal:  Structural characterization of 1,3-bis-tert-butyl monocyclic benzene derivatives with agonistic activity towards retinoid X receptor alpha. (Pubmed Central) -  Nov 15, 2022   
    The results indicate that a bulky substituent at the 5-position is favorable for agonistic activity towards human RXRα. Since 1,3-bis-tert-butyl monocyclic benzene derivatives with bulky hydrophobic moieties differ structurally from known RXRα ligands such as 9-cis-retinoic acid and bexarotene, our findings may be helpful for the development of structural alerts in the safety evaluation of industrial chemicals for RXRα-based toxicity to living organisms.
  • ||||||||||  Targretin oral (bexarotene oral) / ReXceptor
    Journal:  Suppression of amyloid β fibril growth by drug-engineered polymorph transformation. (Pubmed Central) -  Nov 6, 2022   
    As an additional benefit, the bexarotene fibrils kill primary rat hippocampal neurons less efficiently than normal fibrils. In conclusion, the suggested drug-driven polymorph transformation presents a mode of action to irreversibly suppress toxic aggregates not only in Alzheimer's, but also potentially in myriad diverse pathologies that originate with protein condensation.